Category: Biotech

Pfizer And Merck Go For An Even Longer Throw Of The Javelin

Pfizer and Merck KGaA’s tweaks to the Javelin Lung 100 study of their PD-L1 antibody avelumab, which will delay its readout by almost two years, look like a painful but necessary adjustment to commercial realities in this competitive cancer indication. The changes will more than double the size of the study, in first-line non-small cell lung cancer, and push data out to mid-2019.

Ablynx’s Partner, Merck KGaA, Has Presented New Data from a Phase Ib…

GHENT, Belgium, 6 March 2017 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its partner, Merck KGaA , has presented new data from a Phase Ib study demonstrating strong efficacy with the bi-specific anti-IL-17A/F Nanobody® in patients with moderate-to-severe chronic plaque psoriasis. The results were presented at the 75th Annual Meeting of the American Academy of Dermatology Conference, taking place from 3-7 March 2017, in Orlando, Florida.

More Teens Turning Their Backs on Tanning Beds

… indoor tanning appears to give them a false sense of security when they step outdoors into real sunlight, said Guy, a health economist with the CDC’s division of cancer prevention and control. “We also found that among the 1.2 million high school …

Celgene to Present New Data from Clinical Trials on Oral OTEZLA…

Celgene Corporation today announced that findings from ongoing clinical trials of OTEZLA , the Company’s oral, selective inhibitor of phosphodiesterase 4 , conducted in patients with moderate or moderate to severe plaque psoriasis, and in adult patients with active psoriatic arthritis, will be presented at the 75th Annual Meeting of the American Academy of Dermatology in Orlando, Florida. Ten abstracts will be presented at the meeting.

FDA OKs Merck’s allergen extract to treat house dust mite-induced allergic rhinitis

The FDA approves Merck’s Odactra, the first allergen extract that is administered sublingually to treat house dust mite-induced nasal inflammation , with or without eye inflammation in people between the ages of 18 and 65. Odactra, a once-daily tablet that rapidly dissolves under the tongue, exposes patients to house dust mite allergens with the aim of gradually training the immune system to reduce the frequency and severity of nasal and eye allergy symptoms. It is taken year-round.

Surrey woman part of $6.2M drug award

Faith Gibson holds her two-year-old daughter Meah Bartram in 2008. The little girl was born with a hole in her heart, a condition Gibson believes was caused by the doctor-prescribed anti-anxiety medication she was taking while pregnant.

After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B

Perrigo also said it will review its API business, which provides differentiated active pharmaceutical ingredients and finished dosage forms for the branded and generic industries. Perrigo , the Dublin-based manufacturer of over-the-counter drugs, announced Monday it will divest its royalty stream for multiple sclerosis drug Tysabri to an affiliate of Royalty Pharma for up to $2.85 billion.

3 Top Healthcare Stocks to Buy Now

… lthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights

La Jolla’s low blood pressure treatment clears key study

Feb 27 La Jolla Pharmaceutical Co said its lead experimental drug to treat low blood pressure met the main goal of a late-stage study on patients with distributive shock who have not adequately responded to existing treatments. Distributive shock is a state in which the heart is pumping well enough, but the blood is not distributed properly to the vital organs leading to severe hypotention.

Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections

Pfizer Inc. said that it received two subpoenas from the U.S. Attorney’s office in Massachusetts related to charities that help Medicare patients afford co-payments for drugs, the latest company to disclose involvement in the probe. The New York-based drugmaker said in a securities filing Thursday that it received subpoenas on December 2015 and on July 2016 requesting documents related to the Patient Access Network Foundation and other organizations that provide financial assistance to Medicare patients.

Global Alzheimer’s Disease Diagnostic Market is expected to grow at a CAGR over 10% post 2022

Alzheimer’s Disease Diagnostic Market Analysis and Forecast by Type , Diagnostic Test , End Users – 2022 Major Key Players are Eli Lilly and Company , TauRx , Alector LLC , Accera, Inc. , Treventis Corporation , Neuro-Bio Ltd ” PUNE, MAHARASHTRA, INDIA, February 24, 2017 / EINPresswire.com / — Market Highlights Alzheimer’s is a type of dementia which causes failure of the functioning of the brain. This disease damages the areas which is responsible for the thinking, problem solving and behavior process.

New HIV infections fall in the US, but demographic and geographic disparities persist

Public domain image by the National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention www.cdc.gov The number of annual new HIV infections in the US fell by 18% overall since 2008, offering evidence that prevention and treatment efforts are having an impact, according to data from the US Centers for Disease Control and Prevention released on Tuesday to coincide with presentations at the 2017 Conference on Retroviruses and Opportunistic Infections in Seattle. A closer look at the data, however, shows some notable differences across demographic groups and geographic regions.

Why GlaxoSmithKline’s 2017 Guidance Is Conservative

Assuming that Advair will face competition from a substitutable generic in the US by mid-2017, GSK guided for flat to a slight decline in Core EPS at constant exchange rates. The stock is trading at a discount to five years average historical P/E vs. peers and some potential source of earnings upside is expected in 2017.

Health Highlights: Feb. 17, 2017

More deadly heat waves, catastrophic food shortages, and the rapid spread of some infectious diseases are all in the world’s future due to climate change, experts warned Thursday at the Climate & Health Meeting. The meeting, held at the Carter Center in Atlanta, was organized to replace a Centers for Disease Control and Prevention climate change conference that was canceled in January, ahead of President Donald Trump’s inauguration, CNN reported.

Myriad’s Prolaris Test Significantly Improves the Risk…

Myriad Genetics, Inc. , a global leader in personalized medicine, today announced new data demonstrating the utility of the ProlarisA test to more accurately classify mortality risk and guide the management of newly diagnosed men with prostate cancer. The data are being presented at the 2017 Genitourinary Cancers Symposium meeting in Orlando, Fla.

“Superspreaders” identified as driving cause of 2014 Ebola epidemic

A new study has shown that in the catastrophic 2014-2015 Ebola epidemic in West Africa, about three percent of the people infected were responsible for infecting 61 percent of all cases. The issue of so-called “superspreaders,” according to researchers who published their findings in Proceedings of the National Academy of Sciences, is so significant that it’s important to put a better face on just who these people are and then better reach them with public health measures designed to control the spread of infectious disease during epidemics.

ViiV Healthcare announces detailed positive phase III results for…

In the SWORD studies, the two-drug regimen showed comparable efficacy to three- or four-drug regimensin virologically suppressed patients. ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine .

Will Seattle Genetics’ Deal With Immunomedics Get Scuttled?

The deal could be a big win for Seattle Genetics, but it doesn’t have the full support of all of Immunomedics investors. After the closing market bell on Friday, venBio Select Advisors, LLC — the beneficial owner of 9.9% of Immunomedics shares — said Immunomedics’ board of directors is “giving away its crown jewel.”

CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

SCI reported the net income available to common shareholders for the quarter ended December 31, 2016 was $3,536,802 or $0.02 per basic share, versus $2,341,813 or $0.02 per basic share during the quarter ended December 31, 2015. CEL-SCI reported an operating loss of for the quarter ended December 31, 2016 versus an operating loss of for the quarter ended December 31, 2015.

Recent Publication Highlights Proof-of-Concept Data Supporting the…

TUSTIN, Calif., Feb. 09, 2017 — Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform. Results of the study, conducted at University of Texas Southwestern Medical Center, showed researchers were able to distinguish between healthy subjects and patients with ovarian tumors based on the levels of exosomes containing phosphatidylserine found in their plasma.